M&S Decisions, Moscow, Russia.
STU "Sirius", Sochi, Russia.
CPT Pharmacometrics Syst Pharmacol. 2023 Jun;12(6):831-841. doi: 10.1002/psp4.12956. Epub 2023 Mar 16.
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by abnormally high blood glucose concentrations due to dysfunction of the insulin-producing beta-cells in the pancreas. Dapagliflozin, an inhibitor of renal glucose reabsorption, has the potential to improve often suboptimal glycemic control in patients with T1DM through insulin-independent mechanisms and to partially mitigate the adverse effects associated with long-term insulin administration. In this work, we have adapted a systems pharmacology model of type 2 diabetes mellitus to describe the T1DM condition and characterize the effect of dapagliflozin on short- and long-term glycemic markers under various treatment scenarios. The developed platform serves as a quantitative tool for the in silico evaluation of the insulin-glucose-dapagliflozin crosstalk, optimization of the treatment regimens, and it can be further expanded to include additional therapies or other aspects of the disease.
1 型糖尿病（T1DM）是一种自身免疫性疾病，其特征是由于胰腺中产生胰岛素的β细胞功能障碍，导致血糖浓度异常升高。达格列净是一种肾脏葡萄糖重吸收抑制剂，通过胰岛素非依赖性机制有潜力改善 T1DM 患者通常不理想的血糖控制，并部分减轻与长期胰岛素治疗相关的不良反应。在这项工作中，我们对 2 型糖尿病的系统药理学模型进行了改编，以描述 T1DM 病症，并在各种治疗情况下描述达格列净对短期和长期血糖标志物的影响。开发的平台可作为一种定量工具，用于对胰岛素-葡萄糖-达格列净相互作用进行计算机评估、优化治疗方案，并且可以进一步扩展到包括其他疗法或疾病的其他方面。
